Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

被引：0

作者：

Mathew Vithayathil

Antonio D’Alessio

Claudia Angela Maria Fulgenzi

Naoshi Nishida

Martin Schönlein

Johann von Felden

Kornelius Schulze

Henning Wege

Anwaar Saeed

Brooke Wietharn

Hannah Hildebrand

Linda Wu

Celina Ang

Thomas U. Marron

Arndt Weinmann

Peter R. Galle

Dominik Bettinger

Bertram Bengsch

Arndt Vogel

Lorenz Balcar

Bernhard Scheiner

Pei-Chang Lee

Yi-Hsiang Huang

Suneetha Amara

Mahvish Muzaffar

Abdul Rafeh Naqash

Antonella Cammarota

Valentina Zanuso

Tiziana Pressiani

Matthias Pinter

Alessio Cortellini

Masatoshi Kudo

Lorenza Rimassa

David J. Pinato

Rohini Sharma

机构：

[1] Imperial College London,Department of Surgery & Cancer

[2] Hammersmith Campus,Department of Biomedical Sciences

[3] Humanitas University,Division of Medical Oncology

[4] Policlinico Universitario Campus Bio-Medico,Department of Gastroenterology and Hepatology, Faculty of Medicine

[5] Kindai University,Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology

[6] University Medical Center Hamburg-Eppendorf,Department of Gastroenterology and Hepatology

[7] University Medical Center Hamburg-Eppendorf,Division of Medical Oncology, Department of Medicine

[8] Kansas University Cancer Center,Division of Hematology/Oncology, Department of Medicine

[9] Tisch Cancer Institute,I. Medical Department

[10] Mount Sinai Hospital,Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine

[11] University Medical Center Mainz,Division of Gastroenterology & Hepatology, Department of Internal Medicine III

[12] Freiburg University Medical Center,Division of Gastroenterology and Hepatology, Department of Medicine

[13] University of Freiburg,Institute of Clinical Medicine, School of Medicine

[14] University of Freiburg,Division of Hematology/Oncology

[15] Signalling Research Centers BIOSS and CIBSS,Medical Oncology and Hematology Unit

[16] German Cancer Consortium (DKTK),Division of Oncology, Department of Translational Medicine

[17] Hannover Medical School,undefined

[18] Medical University of Vienna,undefined

[19] Taipei Veterans General Hospital,undefined

[20] National Yang Ming Chiao Tung University,undefined

[21] East Carolina University,undefined

[22] Medical Oncology/TSET Phase 1 Program,undefined

[23] Stephenson Cancer Center,undefined

[24] University of Oklahoma,undefined

[25] Humanitas Cancer Center,undefined

[26] IRCCS Humanitas Research Hospital,undefined

[27] University of Piemonte Orientale,undefined

来源：

Hepatology International | 2023年 / 17卷

关键词：

Immunotherapy; Anti-programmed death-ligand; Anti-vascular endothelial growth factor; Checkpoint inhibitor; Obesity; Cirrhosis; Overall survival; Progression-free survival; Overweight; Non-alcoholic fatty liver disease;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：904 / 914

页数：10

共 50 条

[1] Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Vithayathil, Mathew
D'Alessio, Antonio
Fulgenzi, Claudia Angela Maria
Nishida, Naoshi
Schoenlein, Martin
von Felden, Johann
Schulze, Kornelius
Wege, Henning
Saeed, Anwaar
Wietharn, Brooke
Hildebrand, Hannah
Wu, Linda
Ang, Celina
Marron, Thomas U.
Weinmann, Arndt
Galle, Peter R.
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Lee, Pei-Chang
Huang, Yi-Hsiang
Amara, Suneetha
Muzaffar, Mahvish
Naqash, Abdul Rafeh
Cammarota, Antonella
Zanuso, Valentina
Pressiani, Tiziana
Pinter, Matthias
Cortellini, Alessio
Kudo, Masatoshi
Rimassa, Lorenza
Pinato, David J.
Sharma, Rohini
HEPATOLOGY INTERNATIONAL, 2023, 17 (04) : 904 - 914
[2] Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil, Mathew
D'Alessio, Antonio
Fulgenzi, Claudia A. M.
Nishida, Naoshi
Schoenlein, Martin
von Felden, Johann
Schulze, Kornelius
Wege, Henning
Saeed, Anwaar
Wietharn, Brooke
Hildebrand, Hannah
Wu, Linda
Ang, Celina
Marron, Thomas U.
Weinmann, Arndt
Galle, Peter R.
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Lee, Pei-Chang
Huang, Yi-Hsiang
Amara, Suneetha
Muzaffar, Mahvish
Naqash, Abdul Rafeh
Cammarota, Antonella
Personeni, Nicola
Pressiani, Tiziana
Pinter, Matthias
Cortellini, Alessio
Kudo, Masatoshi
Rimassa, Lorenza
Pinato, David J.
Sharma, Rohini
LIVER INTERNATIONAL, 2022, 42 (11) : 2538 - 2547
[3] Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
Rimini, Margherita
Stefanini, Bernardo
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Finkelmeier, Fabian
Yoo, Changhoon
Presa, Jose
Amadeo, Elisabeth
Genovesi, Virginia
De Grandis, Maria Caterina
Iavarone, Massimo
Marra, Fabio
Foschi, Francesco
Tamburini, Emiliano
Rossari, Federico
Vitiello, Francesco
Bartalini, Linda
Solda, Caterina
Tovoli, Francesco
Vivaldi, Caterina
Lonardi, Sara
Silletta, Marianna
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Himmelsbach, Vera
Montes, Margarida
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
LIVER INTERNATIONAL, 2024, 44 (05) : 1108 - 1125
[4] The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
Takeuchi, Yasuto
Nouso, Kazuhiro
Fujioka, Shin-ichi
Kariyama, Kazuya
Kobashi, Haruhiko
Uematsu, Shuji
Moriya, Akio
Hagihara, Hiroaki
Takabatake, Hiroyuki
Nakamura, Shinichiro
Yabushita, Kazuhisa
Kikuchi, Tatsuya
Oyama, Atsushi
Adachi, Takuya
Wada, Nozomu
Onishi, Hideki
Shiraha, Hidenori
Takaki, Akinobu
CANCER MEDICINE, 2023, 12 (17): : 17559 - 17568
[5] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Esmail, Abdullah
Xu, Jiaqiong
Burns, Ethan A.
Abboud, Karen
Sheikh, Ali
Umoru, Godsfavour
Gee, Kelly
Wiechmann, Catherine
Zhang, Yuqi
Abdelrahim, Maen
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
[6] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
D'Alessio, Antonio
Cammarota, Antonella
Zanuso, Valentina
Pressiani, Tiziana
Personeni, Nicola
Rimassa, Lorenza
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
[7] Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab
Ledenko, Matthew
Mercado, Lydia
Patel, Tushar
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (03): : 105 - 109
[8] Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Kurebayashi, Yutaka
Tsujikawa, Hanako
Sugimoto, Katsutoshi
Yunaiyama, Daisuke
Araki, Yoichi
Saito, Kazuhiro
Takahashi, Hiroshi
Kakegawa, Tatsuya
Wada, Takuya
Tomita, Yusuke
Abe, Masakazu
Yoshimasu, Yu
Takeuchi, Hirohito
Hirata, Taiki
Sakamaki, Kentaro
Kakimi, Kazuhiro
Nagao, Toshitaka
Itoi, Takao
Sakamoto, Michiie
HEPATOLOGY RESEARCH, 2023, 53 (10) : 1008 - 1020
[9] 18F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Whi, Wonseok
Lee, Hyunjong
Hong, Jung yong
Kang, Wonseok
Cho, Young seok
Moon, Seung hwan
Choi, Joon young
Lee, Kyung-Han
Hyun, Seung hyup
ANTICANCER RESEARCH, 2025, 45 (03) : 1273 - 1280
[10] Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not
Imai, Kenji
Takai, Koji
Unome, Shinji
Miwa, Takao
Hanai, Tatsunori
Suetsugu, Atsushi
Shimizu, Masahito
Duda, Dan G.
CANCERS, 2024, 16 (02)

← 1 2 3 4 5 →